1. RESPONSE TO NIVOLUMAB AS ≥3rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS. (12th June 2019) Authors: Lepik, K.; Mikhaylova, N.; Kondakova, E.; Tsvetkova, L.; Zalyalov, Y.; Borzenkova, E.; Moiseev, I.; Baykov, V.; Nikitina, T.; Porfir'eva, N.; Ionova, T.; Afanasyev, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗